IGM Biosciences, Inc.: restructuring charge — IGM Biosciences halts hematologic oncology programs, cuts workforce 22%, extends cash runway to Q2 2026

IGM Biosciences, Inc.

Reduces workforce by ~22%; focusing on DR5 agonist in colorectal cancer and T cell engagers in autoimmune diseases.
Halts all hematologic oncology clinical development and targeted cytokine program; continues Sanofi collaboration.
Plans to file IND for IGM-2644 (CD38 x CD3) for autoimmune disease in 2024.
Cash runway now expected into Q2 2026; estimates $1.9M in employee-related restructuring charges.
Enrollment continues in randomized aplitabart colorectal cancer trial (goal ~110 patients by Q1 2024).

item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IGM Biosciences, Inc. announced a restructuring with charges of approximately $1.9 million (approximately 22 percent).

Type: restructuring
Charge: approximately $1.9 million
Headcount: approximately 22 percent

Exact text from the filing

The Company estimates it will incur approximately $1.9 million in employee-related restructuring charges as a result of the Strategic Refocusing, consisting of cash expenditures of $3.9 million from one-time employee benefits and severance costs, offset by non-cash benefits of $2.0 million related to the reversal of previously recognized incentive and stock-based compensation expense.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-23-069045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.